Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Great news & huge congrats all. Another landmark achieved.
I loved the punchy ‘Immediately put test on market’.
We’ll see deal after deal done from now onwards.
Thanks v much. V interesting presentation. March 2019 50M market cap. Moved on great strides since then.
Impressive progress all round and so much more than would have seemed possible back at that event.
One of the most important things I’ve taken from this Toyota business is the clearest evidence, for some time, of the long term commitment. Also, one wonders, what real evidence is emerging that this ain’t going away for the foreseeable future. The solution we have is the best in class and given time, could provide the standard LFT ingredient world wide for many years to come.
Once we are underway, growth of sales should be quite dramatic and most importantly sustained. Decent multiples should apply.
I've just travelled away long haul and it's been pretty horrendous. Our PCRs were to be done within timescales, not too early or too late but no promises of when results given. In a 5-day hotel room electronically tagged quarantine now. PCR again at then end with no commitment on the timing of results so maybe an additional 2 days.
It's never going to work this way. The management of tiny numbers of passengers was well done but nothing like the reality of the real-world volumes. Could so easily be fixed. This quarantine is seriously boring.
We shouldn’t be expecting anything from him. We need the Company to go forth without having to pander to anyone. The tech will speak for itself and be sought after rather than the other way around.
Whether it’s first thing tomorrow or during the next few days, I think this is the beginning of our due reward. All the moons have aligned and whatever the moon is and whatever the market circumstances, most importantly, the technology has a resounding thumbs up.
The long term value in what has been achieved is immense, at any time and is worth an immeasurable fortune once properly applied and rolled out.
Well done all.
Don’t be nervous Ndn. There are so many things in our lives to be nervous about, thankfully now this is no longer one of them.
Good post Energyshares. I don’t know the answer as to how many steps AVA6000 needs success in, in clinical trials, to trigger takeover activity. Perhaps initial trials, should they produce convincing results, would be sufficient to de-risk for an acquirer and possibly attract others. In this case we’d most likely see the SP react significantly, before results were published, so we will know.
Admittedly also the diagnostics business now seems to have a broader and v good future mid and long term aswell, aside from the unknowns of Covid 19. If we don’t end up with vast scale of LFT Covid orders we’d hoped for, the diagnostics will still be very valuable as a recurring revenue steam, for which we’ll be able to add big multiples.
The business is still looking extremely attractive no matter how much I’ve been trying to wean myself off thinking about it over the last few days.
I’ll give you that jdt, of course. It’s quite what I meant though. Just thought the presentation, even though it was delivered very well, sounded a tiny bit replay in parts.
Still in huge awe of the Company, the tech and the opportunity and thrilled to be involved. I’ve probably been unrealistic and expecting a bit too much too soon and all at the same time.
PL, I think my reality is that I thought, although subconsciously, that AS et all were superheroes and I’m now beginning to realise they’re not quite superheroes but still v good.
I’m much less deflated than at the end of last week, following the prolonged and bad mannered silence. Since then and today I’m much more on board with a normal bunch of non superheroes who are de-briefing us fairly well.
I think the tech is def superhuman though and is hopefully in the right hands. Time will tell if it should be in their hands or perhaps in others. Still cool, for now and confident we’ll make bundles, one way or tother.
One of the best things about Avacta is this great board. They should read it more often. Hi all ;)
Pl has assessed the opportunity very well.
I’m sorry to say but I was slightly underwhelmed today-v v slightly deflated.
I’m not overly unhappy, nor am I frightened off but a few things were slightly light in their delivery. I think this sense was also reflected in the market. My views as follows:
LFD production numbers v ambiguous. Far too much TBC.
Bams gone and seemed too easily dismissed.
AVA6000 seemed longer timeline and more hurdles to market than I’d understood (could have been my misunderstanding).
Slightly too disappointing numbers financial year
No presentation of ongoing non Covid revenue projections. (Apologies if I missed them but if they were there).
Main upsides:
Outstanding LFT validation. (Although late and not in the format promised)
High quality presentation of AVA6000 from Neil Bell.
I got the feeling the meeting was slightly ‘rattled off’ to cover the hot spots of investor demand, which of course is understandable.
Despite the presentation, we’ve achieved the best test in the world and with greater ongoing prospects than many and I do feel the Company is undervalued at the moment and will be worth a staggering amount very soon. I think it’s going to considerably exceed the value that many have been expecting.
Must have been a mistake. They meant 285.00 ;)
Spot on Beinthelead. Analysts and investment banks won’t get that initially but it would indeed be worth that and most probably a whole lot more.
I can’t see why anyone would be in any way disappointed with these results, they are truly exceptional. I put up a very ****ed off post on Friday night which was subsequent censored. I’d been angry with the silence which I’d believed they could have dealt with better, which they definitely have now.
The results are great, we now know we have the best test and there’s every reason to think that we will mop up all there is in the market.
The other thing that is especially huge for us is proving the capability of the business ongoing and proving that we have very very valuable IP. We own this technology and the additional opportunities, as we know, are endless.
Well done everyone and thanks to this great BB board for keeping things in check, as always.
Wherever we end up this afternoon or next week, just worth remembering why we’re all really here. It’s unlikely we’ll ever see one like this again.
Interesting to see the deal was done for 17.4B US today. It’s been well justified to holders both sides with big synergies and obvious potential. The deal still carries a big chunk of debt and pays x 50 PPD’s annual profits.
This truly is really is a stunningly attractive sector at the moment. Goodness knows what a fully worked up Avacta looks like if only some of the pipeline proves itself.
Totally agree with you Radiagreen. Also think it will end up bigger and better and extremely well represented globally.
Part 2
Abingdon Health signs collaboration and co-marketing agreement with Abcam
York, and Cambridge U.K. 09 February 2021: Abingdon Health (AIM:ABDX) (“Abingdon” or “the Company”), a leading international developer and manufacturer of high quality and effective rapid tests, has signed a collaboration and co-marketing agreement with Abcam plc (NASDAQ:ABCM; AIM:ABC) (“Abcam”), a global leader in the supply of life science research tools and reagents.
The Parties intend to establish a collaborative strategic relationship to enable them to identify and maximise opportunities for the provision of each Party’s respective products and services, including the wider Abcam reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services.
Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services, for the Company’s lateral flow assays. Custom conjugation reagents will include a combination of an affinity binding reagent such as an antibody, and signal reagents such as the colloidal gold which provides the colour output in a lateral flow assay. Securing a reliable source for custom conjugation reagents ensures reliable supply chains of critical reagents for customers of Abingdon by providing access to the reagents, colloidal gold and specialist conjugation services of Abcam.
Part 1
I’m beginning to think the Abcam opportunity has more to it and significant opportunity. Their catalogue revenue commands chunky multiples. Worth a look:
Abcam Regulatory News. Live ABC RNS. Regulatory News Articles for Abcam Plc Ord 0.2P (lse.co.uk)
Apologies if this has already been covered on the board.
Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector
Scaling up R&D, manufacturing and commercial capabilities in Shanghai and Hangzhou
Investing in state-of-the-art facilities and equipment to support research, diagnostic and clinical applications
CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service, logistics and manufacturing capabilities are strengthening Abcam’s position as a leading collaborator for academia and industry in the region.
Alan Hirzel, CEO, Abcam, said: “Over the 15 years Abcam has been active in China, we have been focused on working closely with scientists to help them accelerate their discoveries and have an impact on society in China and beyond. These facilities represent another step in our growth and, more importantly, allow us to support the growth and importance of Chinese science and its contribution to global wellbeing.”
The size of the Hangzhou facility has been increased by a third to meet the needs of strategic partners and customers focused on research, therapeutic, and in vitro diagnostic applications. With new automation and technology, fully flexible laboratory configurations and a specially designed logistics hub, the facility is driving the growth of Abcam’s high-quality, validated reagent portfolio. In addition, the new 10,000 sq ft Shanghai location is facilitating Abcam’s direct customer support across the region.
The footprint expansion in China is an integral part of the Company’s commitment to sustainably deliver high-quality reproducible reagents to the global life science community.
Really sad to hear the news. Good bloke and did his duty right up to his 90s.